Pacira BioSciences, Inc.
PCRX
$25.22
$0.773.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -247.19% | -337.30% | -1,399.31% | 1,492.14% | 774.03% |
| Total Depreciation and Amortization | 9.58% | 4.25% | -1.26% | -5.78% | -7.66% |
| Total Amortization of Deferred Charges | 19.11% | -14.03% | -40.89% | -52.12% | -59.03% |
| Total Other Non-Cash Items | 273.71% | 184.86% | 144.16% | -19.86% | -26.96% |
| Change in Net Operating Assets | -15.75% | 59.55% | 69.59% | 19.52% | 8.58% |
| Cash from Operations | -4.81% | 22.46% | 36.71% | 31.93% | 38.16% |
| Capital Expenditure | -43.00% | 29.85% | 45.29% | 53.41% | 60.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -930.92% | -178.36% | -164.73% | -129.56% | -90.69% |
| Cash from Investing | -2,138.14% | -207.40% | -192.75% | -171.84% | -108.51% |
| Total Debt Issued | -- | 92.24% | 92.24% | 92.24% | -100.00% |
| Total Debt Repaid | -481.75% | 36.16% | 45.49% | 35.98% | 93.19% |
| Issuance of Common Stock | -47.97% | -51.62% | -55.70% | -65.01% | -73.47% |
| Repurchase of Common Stock | -23,234.55% | -23,948.11% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -421.61% | -345.83% | -345.83% | 100.00% |
| Cash from Financing | 153.80% | 109.49% | 107.32% | 96.63% | 91.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.96% | 151.18% | 1,525.00% | 554.58% | 177.67% |